Royalty Pharma Stock (NASDAQ:RPRX)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$59.02

52W Range

$34.08 - $59.72

50D Avg

$55.49

200D Avg

$45.86

Market Cap

$25.30B

Avg Vol (3M)

$3.75M

Beta

0.42

Div Yield

$0.91 (1.55%)

RPRX Company Profile


Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Show More

Industry

Medical - Pharmaceuticals

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

100

IPO Date

Jun 16, 2020

Website

RPRX Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Royalty Income, Other$117.04M$114.15M$155.97M
Financial Royalty Assets$2.26B$2.15B$2.20B
Intangible Royalty Assets--$835.00K

Fiscal year ends in Dec 25 | Currency in USD

RPRX Financial Summary


Dec 25Dec 24Dec 23
Revenue$2.38B$2.26B$2.35B
Operating Income$1.56B$1.29B$1.49B
Net Income$770.95M$858.98M$1.13B
EBITDA$1.56B$1.56B$1.89B
Basic EPS$1.79$1.92$2.54
Diluted EPS$1.78$1.91$2.53

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26May 06, 26 | 12:00 AM
Q4 25Feb 11, 26 | 8:00 AM
Q3 25Nov 05, 25 | 8:00 AM

Peer Comparison


TickerCompany
ROIVRoivant Sciences Ltd.
SNNSmith & Nephew plc
GMABGenmab A/S
FMSFresenius Medical Care AG & Co. KGaA
EXELExelixis, Inc.
INCYIncyte Corporation
SMMTSummit Therapeutics Inc.
THCTenet Healthcare Corporation
UTHRUnited Therapeutics Corporation